| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.5 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.031 | 0.5 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.018 | 0.5 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.5 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.049 | 0.5 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |